Cowen and Company’s Albireo Pharma Inc ALBO Stock Holding History

Cowen and Company’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-600,000	Closed	-$20M	–	549
2020 Q3	$20M	Buy	+600,000	New	+$17.5M	3.27%	4

Other funds holding ALBO

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Cowen and Company's ALBO Position: Q4 2020 in Review

Cowen and Company sold out of Albireo Pharma Inc (ALBO) in Q4 2020, closing a stake of 600,000 shares — an estimated $20M sold.

Cowen and Company first reported a position in ALBO in Q3 2020 and held it in 1 quarter. The position peaked at $20M in Q3 2020. 107 funds tracked by Wall St. Rank hold ALBO as of Q4 2020.

Cowen and Company reported no remaining Albireo Pharma Inc position as of Q4 2020 after selling out during the quarter.
Cowen and Company sold 600,000 Albireo Pharma Inc shares in Q4 2020, an estimated $20M.
Cowen and Company first reported a position in Albireo Pharma Inc in Q3 2020 and held it in 1 quarter.
Cowen and Company's Albireo Pharma Inc position peaked at $20M in Q3 2020.
107 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2020.

Based on Cowen and Company's 13F filing for Q4 2020, filed 8 Feb 2021.